Atara Biotherapeutics, Inc.
2659 Townsgate Road
Suite 236
Thousand Oaks
California
91361
United States
278 articles about Atara Biotherapeutics, Inc.
-
Layoffs at Atara have begun weeks after the Bay Area company announced plans to terminate 20% of its staff under a new corporate strategy focused on the innovation within the company’s pipeline.
-
Atara Biotherapeutics Announces Second Quarter 2022 Financial Results and Corporate Strategy Update
8/8/2022
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the second quarter 2022, an update to its corporate strategy, recent business highlights, and key upcoming catalysts.
-
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 04, 2022
8/4/2022
Atara Biotherapeutics, Inc. reported the grant of an aggregate of 82,756 restricted stock units of Atara’s common stock to four newly hired employees and stock options to purchase an aggregate of 98,701 shares of Atara’s common stock to two such newly hired employees.
-
Atara Biotherapeutics to Present at the Canaccord Genuity 42nd Annual Growth Conference
8/3/2022
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), today announced that Pascal Touchon, President and Chief Executive Officer, will present at the Canaccord Genuity 42nd Annual Growth Conference on Thursday, August 11, 2022 at 9:00 a.m. PDT / 12:00 p.m. EDT.
-
Atara Biotherapeutics to Announce Second Quarter 2022 Financial Results on Monday, August 8, 2022
8/1/2022
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release second quarter 2022 financial results after market close on Monday, August 8, 2022.
-
Atara announced that it has completed an interim analysis of its Phase II EMBOLD trial for the use of its candidate ATA188 in patients with progressive multiple sclerosis.
-
Atara Biotherapeutics Announces Completion of the ATA188 Phase 2 EMBOLD Study Interim Analysis in Patients with Progressive MS
7/12/2022
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced completion of the planned Interim Analysis (IA) of the ATA188 Phase 2 randomized, placebo-controlled study (EMBOLD) in June 2022.
-
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 02, 2022
7/2/2022
Atara Biotherapeutics, Inc. reported the grant of an aggregate of 31,515 restricted stock units of Atara’s common stock to four newly hired employees and stock options to purchase an aggregate of 15,227 shares of Atara’s common stock to one such newly hired employee.
-
Atara Biotherapeutics Announces First Clinical Data from Ongoing Tab-cel® European Multicenter Expanded Access Program (EAP) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and Update on Tab-cel EMA Regulatory Progress
6/4/2022
Atara Biotherapeutics, Inc., a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, announced EMA regulatory progress and tabelecleucel clinical outcomes.
-
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 03, 2022
6/3/2022
Atara Biotherapeutics, Inc. reported the grant of an aggregate of 126,928 restricted stock units of Atara’s common stock to four newly hired employees and stock options to purchase an aggregate of 186,378 shares of Atara’s common stock to three such newly hired employees.
-
Bayer has terminated a two year-old partnership with Atara to develop off-the-shelf T-cell immunotherapy for high mesothelin-expressing tumors.
-
Atara Biotherapeutics Provides Update on Strategic Collaboration with Bayer
5/19/2022
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that it received notification of Bayer’s intention to end the exclusive worldwide licensing agreement for next-generation mesothelin-directed CAR T-cell therapies.
-
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 06, 2022
5/6/2022
Atara Biotherapeutics, Inc. reported the grant of an aggregate of 115,059 restricted stock units of Atara’s common stock to 13 newly hired employees and stock options to purchase an aggregate of 118,745 shares of Atara’s common stock to eight such newly hired employees.
-
Atara Biotherapeutics Announces First Quarter 2022 Financial Results and Operational Progress
5/5/2022
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the first quarter 2022, recent business highlights and key upcoming catalysts.
-
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 29, 2022
4/29/2022
Atara Biotherapeutics, Inc. reported the grant of inducement awards to Charlene Banard, its new Executive Vice President, Chief Technical Officer.
-
Atara Biotherapeutics to Announce First Quarter 2022 Financial Results on Thursday, May 5, 2022
4/28/2022
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release first quarter 2022 financial results after market close on Thursday, May 5, 2022.
-
Patient deaths associated with Astellas Pharma’s gene therapy candidate underscore the risks of developing potential one-and-done treatment options for serious diseases.
-
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 22, 2022
4/22/2022
Atara Biotherapeutics, Inc., a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, reported the grant of inducement awards to Brian Robinson, its new Senior Vice President, Global Medical Affairs.
-
There are an estimated 2.3 million people living with Multiple Sclerosis and hundreds of thousands more undiagnosed, adding up to an annual cost of nearly $85 billion for care in the United States.
-
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 08, 2022
4/8/2022
Atara Biotherapeutics, Inc., a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, reported the grant of an aggregate of 37,538 restricted stock units of Atara’s common stock to five newly hired employees.